- Home
- SACH vs DTIL Comparison
SACH vs DTIL Comparison
Compare SACH & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- DTIL
- Stock Information
- Founded
- SACH 2010
- DTIL 2006
- Country
- SACH United States
- DTIL United States
- Employees
- SACH N/A
- DTIL N/A
- Industry
- SACH Real Estate Investment Trusts
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- DTIL Health Care
- Exchange
- SACH Nasdaq
- DTIL Nasdaq
- Market Cap
- SACH 61.5M
- DTIL 51.6M
- IPO Year
- SACH 2017
- DTIL 2019
- Fundamental
- Price
- SACH $1.17
- DTIL $4.65
- Analyst Decision
- SACH Hold
- DTIL Strong Buy
- Analyst Count
- SACH 4
- DTIL 2
- Target Price
- SACH $2.25
- DTIL $47.00
- AVG Volume (30 Days)
- SACH 191.7K
- DTIL 582.0K
- Earning Date
- SACH 08-13-2025
- DTIL 07-31-2025
- Dividend Yield
- SACH 17.17%
- DTIL N/A
- EPS Growth
- SACH N/A
- DTIL N/A
- EPS
- SACH N/A
- DTIL N/A
- Revenue
- SACH N/A
- DTIL $51,141,000.00
- Revenue This Year
- SACH N/A
- DTIL N/A
- Revenue Next Year
- SACH $4.52
- DTIL $53.21
- P/E Ratio
- SACH N/A
- DTIL N/A
- Revenue Growth
- SACH N/A
- DTIL N/A
- 52 Week Low
- SACH $0.80
- DTIL $3.61
- 52 Week High
- SACH $2.75
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- SACH 51.72
- DTIL 50.95
- Support Level
- SACH $1.14
- DTIL $4.27
- Resistance Level
- SACH $1.35
- DTIL $4.87
- Average True Range (ATR)
- SACH 0.06
- DTIL 0.26
- MACD
- SACH -0.01
- DTIL 0.04
- Stochastic Oscillator
- SACH 23.81
- DTIL 72.15
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.